Do you have published research demonstrating that the sample collection process (and the 80uL specifically) is sufficiently precise to detect and quantify these metabolites into clinically meaningful ranges? This was the core problem with Theranos IIRC. I've quickly reviewed your sources below and they seem to be related to the clinical value of metabolites, I haven't seen one describing precision of the device itself.

I see you mention Theranos, but to be honest, this won't be the last time you get asked these questions. Every partner, news interview, and many potential customers will bring it up. So much so, that I would create a page specifically addressing these issues (in more detail than the FAQ).